Nalaganje...
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs...
Shranjeno v:
| izdano v: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Impact Journals LLC
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5341894/ https://ncbi.nlm.nih.gov/pubmed/27589687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11750 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|